Literature DB >> 8569

Ability of H-2 regions to induce graft-vs-host disease.

J Klein, C L Chiang.   

Abstract

Individual young adult F1 hybrid mice were irradiated with 500 R and 24 hr later injected with 5 X 10(7) spleen cells obtained from a sex-matched parental-strain donor. The injected animals were then followed for a period of 3 months and loss of body weight, mortality rate, and other signs of fatal graft-vs-host disease (GVHD) were recorded. The donor-recipient strain combinations were selected in such a way as to provide genetic differences in the entire H-2 complex, the K or D regions alone, the K or the D end, and the central (I) regions alone. The data obtained on only few combinations indicate that strong GVHD (100% mortality rate within the first month after the injection) occurs only in those donor-recipient combinations which differ in the entire H-2 complex or in the K end (K + I regions). Much weaker GVHD (mortality rate of only 50% or less and death of individual mice spread over the entire observation period) is observed when the donor and the host differ in either the K, I, or D region alone. The degree of GVHD induced by three regions, when taken singularly, is about the same. Surprisingly, the K-region GVHD was somewhat stronger in combinations of mutant strains in comparison with recombinant-strain combinations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 8569

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences.

Authors:  J Sprent; M Schaefer; D Lo; R Korngold
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

2.  Genetic resistance of CBA and A mice to transplanted lymphoid and hemopoietic cells of CBA.M523 mutants and their F1 hybrids.

Authors:  L N Fontalin; T K Kondratjeva; T K Novikova; Z K Blandova
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

3.  Selective transplantation. An emerging concept.

Authors:  P S Russell
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

4.  Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T helper cell clones.

Authors:  P V Lehmann; G Schumm; D Moon; U Hurtenbach; F Falcioni; S Muller; Z A Nagy
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

5.  Prevention of oral tolerance induction to ovalbumin and enhanced antigen presentation during a graft-versus-host reaction in mice.

Authors:  S Strobel; A M Mowat; A Ferguson
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

6.  The role of H-2 and Ia antigens in graft-versus-host reactions (GVHR). Presence of host alloantigens on donor cells after GVHR and suppression of GVHR with an anti-Ia antiserum against hose Ia antigens.

Authors:  G J Prud'homme; U Sohn; T L Delovitch
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

7.  Protection against graft vs. host-associated immunosuppression in F1 mice. I. Activation of F1 regulatory cells by host-specific anti-major histocompatibility complex antibodies.

Authors:  U Hurtenbach; D H Sachs; G M Shearer
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

8.  Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A.

Authors:  A G Rolink; S T Pals; E Gleichmann
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

9.  Role of Ia antigens in graft vs. host reactions. II. Molecular and functional analysis of T cell alloreactivity by the characterization of host Ia antigens on alloactivated donor T cells.

Authors:  T L Delovitch; J F Harris; R Battistella; K Kaufman
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Graft-vs.-host-associated immune suppression is activated by recognition of allogeneic murine I-A antigens.

Authors:  G M Shearer; R B Levy
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.